OPTI-ON: A Longitudinal Real-World Study of Opicapone in Patients with Parkinson’s Disease and Motor Fluctuations
Objective: To conduct a longitudinal real-world study that examines treatment patterns, clinical outcomes, safety and tolerability of opicapone as an adjunctive treatment to carbidopa/levodopa (CD/LD)…Subcutaneous Levodopa Infusion for Parkinson’s disease Patients with Motor Fluctuations: Open-Label Efficacy Outcomes from the BeyoND study
Objective: To review one-year exploratory efficacy data from the ND0612 BeyoND study. Background: ND0612 is an investigational subcutaneous delivery system providing minimally invasive, continuous infusion…The mitochondrial targeted drug SBT-272 attenuates dopaminergic neuron loss, alpha-synuclein burden and neuroinflammation in a mouse model of Parkinson’s Disease
Objective: To assess the preclinical efficacy of the investigational drug SBT-272 in a mouse model of Parkinson’s Disease (PD). Background: SBT-272 is a peptidomimetic drug…Levodopa-Carbidopa Intestinal Gel Therapy for Advanced Parkinson’s Disease: A Single Center ‘Real World’ Study of Patients with and without DBS
Objective: To examine the efficacy and safety of LCIG in a ‘real world’ tertiary care center setting in patients with and without DBS. Background: Levodopa-Carbidopa…Adherence to medication among Serbian Parkinson’s disease patients: a cross-sectional study
Objective: This study aimed to explore patients’ adherence to antiparkinsonian medication, and to determine factors associated with low adherence among Serbian PD patients. Background: Adherence…Evaluation of a double-target therapeutic in preclinical models of Parkinson’s disease
Objective: To evaluate the effectiveness of a candidate compound identified in a high-throughput screening (HTS) assay carried out in a Drosophila model of Parkinson’s disease…Inhibition of GluN2D-containing NMDA receptors alleviates the loss of dopaminergic neurons and behavioral deficits in 6-OHDA-induced model of Parkinson’s disease
Objective: The aim of this study is to explore whether the inhibition of GluN2D-containing NMDA receptors (NMDAR2D) can delay the pathological manifestations of Parkinson's disease…Time to diagnosis of clinically established Parkinson’s disease or atypical parkinsonism: is a 5-year follow-up period necessary?
Objective: To determine the time frame to the diagnosis of clinically established Parkinson’s disease (PD) or atypical parkinsonism after an acute levodopa challenge (LDC) for…Rapidly progressive dementia after MRI-guided Focused Ultrasound (MR-FUS)
Objective: To present a Parkinson´s Disease (PD) patient who presented a rapidly progressive dementia after MR-FUS therapy. Background: MR-FUS thalamotomy is used for unilateral essential…Mild cognitive impairment does not predict development of dementia up to 15 years after subthalamic deep brain stimulation in Parkinson’s disease
Objective: This is a long-term follow-up study of a group of patients with levo-dopa responsive fluctuating Parkinson’s disease (PD), with focus on the short- and…
Abstracts from the International Congress of Parkinson’s and Movement Disorders.